FDA-cleared to identify plaque and patients
at increased risk of MACE

EXPERIENCE BETTER RESULTS FOR YOUR PATIENTS
– AND BETTER RESULTS FOR YOU

There are still broad swaths of uncharted territories concerning the role lipid core plaques play in heart disease. Now, you can achieve unparalleled insights with the Dualpro™ IVUS+NIRS catheter and its accompanying Makoto Intravascular Imaging System, the only FDA-cleared dual-modality catheter and imaging system indicated for the detection of lipid core plaque (LCP) and the identification of plaque and patients at higher risk of major adverse cardiac events (MACE).

By analyzing both structural and compositional data, you can learn about the effects of specific treatments on plaque size and lipid core content, develop novel preventative approaches for plaque stabilization, study regression of plaque size and composition, or guide the use of existing therapies.

The system automatically quantifies the total lipid core in regions of interest as the Lipid Core Burden Index (LCBI). LCBI numbers can be directly compared with prior validation studies for greater understanding of the underlying tissue pathology and to make associations with the published literature for outcomes related to LCBI.